Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEXYCU for Ocular Pain in Cataract Surgery
NCT05550363Phase 3Withdrawn
- Sponsor
- EyePoint Pharmaceuticals
- Start
- Sep 2022
- Primary completion
- Sep 2023
- Modality
- Polymer-based Nanoparticles, Small Molecules
01
Overview
Phase 3, randomised, double-blind trial comparing DEXYCU with Placebo (2 arms). Primary endpoint: Proportion of subjects with absence of ocular pain (score of '0') in the study eye at Day 8. Planned start Sep 2022; status: withdrawn.
02
Drugs
IBI-10090
Beyond the preview
Go deeper on NCT05550363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05550363.